NAVROGEN


Associated tags: HIO, Patient, Neoplasm, Physician, Engineering, Drug, Vaccine, Pharmaceutical industry, Triple-negative breast cancer, CRADA, Development, Non-small-cell lung carcinoma, MRC Laboratory of Molecular Biology, Cancer, Molecular biology, Cooperative research and development agreement, NCI, Laboratory, Thorax

Locations: PENNSYLVANIA, CALIFORNIA

Navrogen Presents Its Anti-CD20 Antibody NAV-006 and ICAM-1 Refractory Antibody-Drug Conjugate Platform at the 2024 American Association for Cancer Research Annual Meeting

Retrieved on: 
Thursday, April 4, 2024
Conference, Rituximab, B-cell lymphoma, Serum, HIO, Patient, CD20, Humoral immunity, Cancer, BRITE, NHL, AACR, CA125, ADC, Lymphoma, CD19, Vaccine

Recent clinical evidence suggests that high serum levels of the tumor-produced MUC16/CA125 protein has a negative impact on the efficacy of rituximab.

Key Points: 
  • Recent clinical evidence suggests that high serum levels of the tumor-produced MUC16/CA125 protein has a negative impact on the efficacy of rituximab.
  • Navrogen will present data showing NAV-006's superior efficacy over rituximab in animal models of human NHL.
  • "We have engineered a trastuzumab-drug conjugate variant with superior cytotoxicity against ICAM-1 positive cancer cells.
  • We are now building a portfolio of enhanced ADCs using this platform to advance internal as well as partnered ADC programs".

Navrogen Enters into CRADA with The U.S. National Cancer Institute for the Clinical Development of NAV-001, an Anti-Mesothelin Antibody-Drug Conjugate

Retrieved on: 
Monday, November 7, 2022
Drug, MRC Laboratory of Molecular Biology, Laboratory, Neoplasm, NCI, National, Physician, Cooperative research and development agreement, Molecular biology, Cancer, Non-small-cell lung carcinoma, Engineering, Development, CRADA, HIO, Patient, Triple-negative breast cancer, Program, Pharmaceutical industry, Vaccine, Thorax

PHILADELPHIA, Nov. 7, 2022 /PRNewswire/ --Navrogen, Inc. announced today that it has entered into a Cooperative Research and Development Agreement (CRADA) with researchers at the U.S. National Cancer Institute (NCI), part of the National Institutes of Health.

Key Points: 
  • PHILADELPHIA, Nov. 7, 2022 /PRNewswire/ --Navrogen, Inc. announced today that it has entered into a Cooperative Research and Development Agreement (CRADA) with researchers at the U.S. National Cancer Institute (NCI), part of the National Institutes of Health.
  • Under this CRADA, Navrogen will sponsor the clinical investigation of the experimental antibody-drug conjugate, NAV-001, under the supervision of Dr. Raffit Hassan, Chief of Thoracic and GI Malignancies Branch at the NCI.
  • "NAV-001 has proven to be very effective with single, sub-mg/kg dosing against various patient-derived tumor types in mouse models, causing significant regression of the cancer lesions."
  • Navrogen is a biotechnology company focused on the discovery of tumor-produced Humoral Immuno-Oncology (HIO) factors that are associated with suppressed humoral immunity, poor prognosis and limited therapeutic response of immune-mediated anti-cancer therapies.